APTVAptiv
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $1.42Beat
- vs $1.33 expected on Nov 3
- Stock move on it
- −6.53%
- one session
- Typical move
- ±4.6%
- average over 2 reports
- Price
- $38.79
- −1.57% today · $12.3B cap
Past and upcoming reports
2
| Nov 3, 2026 | Sep 30, 2026 | Time not given | $1.33 | Beat$1.42 | −6.53% |
| Jul 30, 2026 | Jun 30, 2026 | Time not given | $1.42 | not recorded | −2.59%2d |
After the report
Jul 30, 2026 report
This covers the Jul 30, 2026 report. The Nov 3, 2026 numbers are in the table above.
Aptiv Slides 2.8% After Q2 Report. Market Awaits Aug 4 Guidance
Aptiv reported Q2 2026 results on July 30. Actual EPS not yet confirmed. consensus was $1.42. The stock fell 2.8% the following day, trading at $56.48, below all major moving averages. Analysts remain bullish (14 buys, target $78.54), but technicals show a death cross and weak momentum. The next catalyst is the Aug 4 BMO earnings call, where forward guidance will be critical.
Reported against expected
Actual EPS not available. consensus estimate was $1.42. Stock declined 2.8% post-report, indicating market disappointment.
Guidance
Not provided. next quarter's guidance will be released Aug 4.
How the stock reacted
Closed at $56.48 on July 31, down 2.77% from prior close of $58.09, with volume 3.83M (elevated).
What changed
Stock fell 2.8% post-earnings, extending 1-month decline to -6.3%.
What the price now assumes
Market pricing in fundamental uncertainty. price below all MAs and RSI at 35.9 signal bearish momentum.
What it means for the business
Downgrade bias. wait for Aug 4 guidance to confirm inflection or further weakness.
The next one to three months, as we saw it then
Better case25%
Guidance surprises positively, reversing technical breakdown.
Base case50%
Guidance in line. stock remains range-bound $55-$60 until clearer demand signals.
Worse case25%
Guidance disappoints, accelerating decline toward $50.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.